IPO registrations (S-1, F-1) · Registrants
Sonoma Pharmaceuticals, Inc.
- SEC CIK
- 1367083 · filings on EDGAR ↗
- Former names
- Oculus Innovative Sciences, Inc. (2002–2016)
- Registration
- Form S-1, first filed 2006-07-03, last 2026-04-23; 8 initial registrations, 20 amendments
- Outcome
- Final prospectus filed 2007-01-26; declared effective 2007-01-24
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- 5445 CONESTOGA COURT, SUITE 150, Boulder, CO 80301
- EIN
- 68-0423298
- Ticker
- SNOA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Sonoma Pharmaceuticals, Inc. on the corporate pages
On this site
- Business registration: SONOMA PHARMACEUTICALS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Sonoma Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: Sonoma Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: SONOMA PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: SONOMA PHARMACEUTICALS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: SONOMA PHARMACEUTICALS INC. EXACT (EIN (EXACT))
- SEC filer: Oculus Innovative Sciences, Inc. EXACT (CIK (EXACT))
- Person page: Gregg H Alton Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 49
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2006-07-03 | S-1 | S-1 (registration) | Oculus Innovative Sciences, Inc. | 0000950134-06-012612 ↗ |
| 2006-09-18 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950134-06-017848 ↗ |
| 2006-11-13 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950134-06-021230 ↗ |
| 2006-12-01 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000891618-06-000489 ↗ |
| 2006-12-18 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950134-06-023267 ↗ |
| 2006-12-20 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950134-06-023485 ↗ |
| 2007-01-03 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950134-07-000071 ↗ |
| 2007-01-08 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950134-07-000249 ↗ |
| 2007-01-24 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-07-000280 ↗ |
| 2007-01-26 | 424B4 | 424B4 (final prospectus) | Oculus Innovative Sciences, Inc. | 0000950134-07-001360 ↗ |
| 2007-08-30 | S-1 | S-1 (registration) | Oculus Innovative Sciences, Inc. | 0000891618-07-000530 ↗ |
| 2007-09-12 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-07-003649 ↗ |
| 2008-02-26 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-08-000657 ↗ |
| 2009-03-09 | S-1 | S-1 (registration) | Oculus Innovative Sciences, Inc. | 0000950134-09-004751 ↗ |
| 2009-03-24 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950134-09-005959 ↗ |
| 2009-03-26 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-09-000730 ↗ |
| 2009-04-10 | S-1 | S-1 (registration) | Oculus Innovative Sciences, Inc. | 0000950134-09-007341 ↗ |
| 2009-05-22 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000891618-09-000185 ↗ |
| 2009-06-17 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950123-09-014533 ↗ |
| 2009-07-09 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950123-09-021281 ↗ |
| 2009-07-21 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0000950123-09-023694 ↗ |
| 2009-07-24 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-09-002037 ↗ |
| 2009-07-28 | S-1MEF | S-1MEF (added securities) | Oculus Innovative Sciences, Inc. | 0000950123-09-026425 ↗ |
| 2009-09-03 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-09-002452 ↗ |
| 2011-05-03 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-11-001373 ↗ |
| 2011-12-02 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-11-003446 ↗ |
| 2014-07-21 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-14-002178 ↗ |
| 2014-11-21 | S-1 | S-1 (registration) | Oculus Innovative Sciences, Inc. | 0001019687-14-004450 ↗ |
| 2015-01-07 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0001019687-15-000099 ↗ |
| 2015-01-13 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0001019687-15-000167 ↗ |
| 2015-01-16 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0001019687-15-000215 ↗ |
| 2015-01-20 | S-1/A | S-1/A (amendment) | Oculus Innovative Sciences, Inc. | 0001019687-15-000253 ↗ |
| 2015-01-20 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-15-000146 ↗ |
| 2015-08-06 | EFFECT | EFFECT (declared effective) | Oculus Innovative Sciences, Inc. | 9999999995-15-002213 ↗ |
| 2017-11-27 | EFFECT | EFFECT (declared effective) | Sonoma Pharmaceuticals, Inc. | 9999999995-17-003064 ↗ |
| 2018-10-12 | S-1 | S-1 (registration) | Sonoma Pharmaceuticals, Inc. | 0001683168-18-003037 ↗ |
| 2018-11-07 | S-1/A | S-1/A (amendment) | Sonoma Pharmaceuticals, Inc. | 0001683168-18-003262 ↗ |
| 2018-11-16 | S-1/A | S-1/A (amendment) | Sonoma Pharmaceuticals, Inc. | 0001683168-18-003469 ↗ |
| 2018-11-16 | EFFECT | EFFECT (declared effective) | Sonoma Pharmaceuticals, Inc. | 9999999995-18-002915 ↗ |
| 2020-12-22 | EFFECT | EFFECT (declared effective) | Sonoma Pharmaceuticals, Inc. | 9999999995-20-003625 ↗ |
| 2023-09-19 | S-1 | S-1 (registration) | Sonoma Pharmaceuticals, Inc. | 0001683168-23-006550 ↗ |
| 2023-10-13 | S-1/A | S-1/A (amendment) | Sonoma Pharmaceuticals, Inc. | 0001683168-23-007167 ↗ |
| 2023-10-26 | EFFECT | EFFECT (declared effective) | Sonoma Pharmaceuticals, Inc. | 9999999995-23-003093 ↗ |
| 2023-10-30 | 424B4 | 424B4 (final prospectus) | Sonoma Pharmaceuticals, Inc. | 0001683168-23-007475 ↗ |
| 2023-11-20 | EFFECT | EFFECT (declared effective) | Sonoma Pharmaceuticals, Inc. | 9999999995-23-003391 ↗ |
| 2026-04-17 | S-1 | S-1 (registration) | Sonoma Pharmaceuticals, Inc. | 0001683168-26-003052 ↗ |
| 2026-04-23 | S-1/A | S-1/A (amendment) | Sonoma Pharmaceuticals, Inc. | 0001683168-26-003139 ↗ |
| 2026-04-23 | EFFECT | EFFECT (declared effective) | Sonoma Pharmaceuticals, Inc. | 9999999995-26-001319 ↗ |
| 2026-04-27 | 424B4 | 424B4 (final prospectus) | Sonoma Pharmaceuticals, Inc. | 0001683168-26-003212 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Akao Akihisa | Director | 2 | 2007 | ||
| Alimi Hojabr | Director,Officer | CEO, President; Chief Executive Officer; President & CEO | 13 | 2007–2012 | |
| Brown Edward M | Director | 2 | 2007 | ||
| Burlingame Robert | Director | 10 | 2007–2010 | ||
| Conley Richard K | Director | 20 | 2007–2013 | ||
| French Gregory M | Director; Director,Officer | Chief Operating Officer | 22 | 2007–2013 | |
| Miller Robert E | Officer; Other | Chief Financial Officer | 26 | 2007–2019 | |
| Schutz James J | Director,Officer; Officer; Other | Chief Executive Officer; Chief Operating Officer; Vice President | 32 | 2007–2019 | |
| Thornton Bruce | Officer | Chief Operating Officer; COO; Executive Vice President; Executive VP and COO; Executive VP & COO; Vice President | 10 | 2007–2025 | |
| Wokasch Michael | Officer | Chief Operating Officer | 2 | 2007 | |
| Birnbaum Jay E | Director | 39 | 2007–2026 | ||
| Redhair Dana | Officer | Vice President | 2 | 2007 | |
| Alton Gregg H | Director | 10 | 2008–2012 | person page Fuzzy | |
| Carpenter Michelle | Officer | VP of Regulatory and Quality | 2 | 2008 | |
| Harish Sameer | Other | 2 | 2013 | ||
| MCLAUGHLIN JOHN | Director | 29 | 2013–2026 | ||
| Harrison Russell Joseph | Director | 18 | 2014–2018 | ||
| BARBARI SHARON SURREY | Director | 17 | 2014–2018 | ||
| Northey Robert Allen | Officer | Exec. VP of Res & Development; Exec. VP of Res & Devlpment; Exe. VP of Research and Dev. | 4 | 2015–2017 | |
| Umscheid Marc | Officer | Chief Strategy/Mkt Officer | 6 | 2017 | |
| Weigerstorfer Philippe | Director | 6 | 2018–2026 | ||
| Sandford Frederick J | Director,Officer | CEO and Interim CFO | 2 | 2018–2019 | |
| Dal Poggetto John | Officer | Chief Financial Officer; Controller | 10 | 2019–2026 | |
| Trombly Amy Moss | Officer | Chief Executive Officer; Interim CEO | 12 | 2019–2026 | |
| Edwards Robert Grant | Officer | Chief Financial Officer | 2 | 2020 | |
| DVONCH JEROME J | Officer | Chief Financial Officer; Interim CFO | 10 | 2020–2026 | |
| White Chad Norman | Officer | Chief Financial Officer; Interim CFO | 2 | 2022 | |
| Jacoby Vanessa | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.